The article presents a methodical approach for prediction of life expectancy for people diagnosed with prostate cancer based on the kinetic theory of aging of living systems. The life expectancy is calculated by solving the differential equation for the rate of aging for three different stage of life - «normal» life, life with prostate cancer and life after combination therapy for prostate cancer. The mathematical model of aging for each stage of life has its own parameters identified by the statistical analysis of healthcare data from the Zharinov's databank and Rosstat CDR NES databank. The core of the methodical approach is the statistical correlation between growth rate of the prostate specific antigen level (PSA-level) or the PSA doubling time (PSA DT) before therapy, and lifespan: the higher the PSA DT is, the greater lifespan. The patients were grouped under the «fast PSA DT» and «slow PSA DT» categories. The satisfactory matching between calculations and experiment is shown. The prediction error of group life expectancy is due to the completeness and reliability of the main data source. A detailed monitoring of the basic health indicators throughout the each person life in each analyzed group is required. The absence of this particular information makes it impossible to predict the individual life expectancy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Trends in global and regional incidence and prevalence of hypertensive disordersin pregnancy (1990-2021): an age-period-cohort analysis.
Sci Rep
January 2025
Department of Gynecology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, 750002, Ningxia, China.
Hypertensive disorders of pregnancy (HDP) are significant global health issues. This study utilized data from the Global Burden of Disease Study 2021 to analyze trends in incidence, prevalence, and Disability-Adjusted Life Years (DALY) associated with HDP across 204 countries from 1990 to 2021. The analysis employed estimated annual percentage changes and an age-period-cohort model, stratifying data by age, year, geographical region, and sociodemographic index (SDI).
View Article and Find Full Text PDFClaudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial.
Lancet Oncol
January 2025
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China. Electronic address:
Background: CMG901 is a novel first-in-class antibody-drug conjugate with a humanised anticlaudin 18.2 antibody linked to microtubule-disrupting agent monomethyl auristatin E. We aimed to assess the antitumour activity and safety of CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer and other solid tumours.
View Article and Find Full Text PDFThe pathobiology of neurovascular aging.
Neuron
January 2025
Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA. Electronic address:
As global life expectancy increases, age-related brain diseases such as stroke and dementia have become leading causes of death and disability. The aging of the neurovasculature is a critical determinant of brain aging and disease risk. Neurovascular cells are particularly vulnerable to aging, which induces significant structural and functional changes in arterial, venous, and lymphatic vessels.
View Article and Find Full Text PDFExploring Caspase-3 overexpression in pheochromocytoma cells: Implications for cancer therapy.
Tissue Cell
January 2025
Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address:
Malignant pheochromocytomas are infrequent tumors that have a poorer prognosis compared to their benign counterparts. The administration of chemotherapy to patients with pheochromocytoma can result in adverse side effects and a reduced life quality. Alternative and more targeted treatment strategies, such as gene therapy significantly improve the patients' survival rate and life expectancy.
View Article and Find Full Text PDFRecruitment, follow-up and survival in an 11-country cohort study of patients at the end of life and their relatives.
PLoS One
January 2025
Institute for Palliative Care, Region Skåne and Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Background: Large, international cohort studies generate high-level evidence, but are resource intense. In end-of-life care such studies are scarce. Hence, planning for future studies in terms of data on screening, recruitment, retention and survival remains a challenge.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!